z-logo
open-access-imgOpen Access
Best Practices in Bioassay Development to Support Registration of Biopharmaceuticals
Author(s) -
John R. White,
Marla Abodeely,
Sammina Ahmed,
Gaël Debauve,
Evan Johnson,
Debra M. Meyer,
Ned M. Mozier,
Matthias Naumer,
Alessandra Pepe,
Isam Qahwash,
Edward Rocnik,
Jeffrey G. Smith,
Elaine S. E. Stokes,
Jeffrey J. Talbot,
Pin Yee Wong
Publication year - 2019
Publication title -
biotechniques
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.617
H-Index - 131
eISSN - 1940-9818
pISSN - 0736-6205
DOI - 10.2144/btn-2019-0031
Subject(s) - bioassay , biochemical engineering , drug discovery , drug development , quality (philosophy) , microbiology and biotechnology , computer science , computational biology , risk analysis (engineering) , biology , engineering , business , pharmacology , bioinformatics , drug , ecology , philosophy , epistemology
Biological activity is a critical quality attribute for biopharmaceuticals, which is accurately measured using an appropriate relative potency bioassay. Developing a bioassay is a complex, rigorous undertaking that needs to address several challenges including modelling all of the mechanisms of action associated with the biotherapeutic. Bioassay development is also an exciting and fast evolving field, not only from a scientific, medical and technological point of view, but also in terms of statistical approaches and regulatory expectations. This has led to an industry-wide discussion on the most appropriate ways to develop, validate and control the bioassays throughout the drug lifecycle.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom